Outlook Therapeutics (OTLK) stock: insider trades, news & valuation
Strong buyingShare price and insider trades
Outlook Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 5 insiders bought $7.9M and 0 sold $0 of OTLK stock on the open market, including a cluster buy that began May 26, 2026.
Get emailed when insiders cluster-buy stocks like OTLK
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
OTLK insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | $2.6M | 2 | — | 0 |
| Q2 2026 | $5.3M | 6 | — | 0 |
Valuation, profit and volume
Summary
Over the past 12 months, 5 Outlook Therapeutics, Inc. insiders reported open-market purchases totaling $7.9M, while 0 insiders reported sales totaling $0. The most recent cluster buy began on May 26, 2026, when 4 insiders bought a combined $5.3M. Among insiders with enough purchase history to measure, Yezan Munther Haddadin (Director) has the highest Insider Score at 36.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Aug 14SEC | Ghiath M. SukhtianDirector | Buy | 2,525,25224,617,320 held (+11%) | $0.99 | $2.5M | -39.5% | — |
| Aug 14SEC | Lawrence A KenyonCFO | Buy | 101,010106,956 held (+1699%) | — | $0 | — | — |
| Aug 14SEC | Robert Charles JahrCEO | Buy | 151,515new position | — | $0 | — | — |
| Jul 29SEC | Faisal Ghiath SukhtianDirector | Buy | 95,398220,972 held (+76%) | $1.05 | $100K | -43.0% | — |
| Jun 3SEC | Yezan Munther HaddadinDirector | Buy | 29,00066,167 held (+78%) | $0.83 | $24K | -27.8% | 36 |
| Jun 1SEC | Ventures & Investments GmsDirector | Buy | 8,539,70922,092,068 held (+63%) | $0.59 | $5.0M | +1.5% | — |
| May 27SEC | Kurt J HilzingerDirector | Buy | 400,000423,655 held (+1691%) | $0.44 | $176K | +36.1% | — |
| May 27SEC | Faisal Ghiath SukhtianDirector | Buy | 122,174125,574 held (+3593%) | $0.41 | $50K | +46.1% | — |
| May 27SEC | Yezan Munther HaddadinDirector | Buy | 34,00037,167 held (+1074%) | $0.44 | $15K | +36.1% | 36 |
| May 27SEC | Randy H ThurmanDirector | Buy | 5,0005,593 held (+843%) | $0.43 | $2K | +39.3% | — |
Insiders at Outlook Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Ventures & Investments GmsDirector | $5.0M | — | Jun 1, 2026 | — |
| Ghiath M. SukhtianDirector | $2.5M | — | Aug 14, 2026 | — |
| Kurt J HilzingerDirector | $176K | — | May 27, 2026 | — |
| Faisal Ghiath SukhtianDirector | $150K | — | Jul 29, 2026 | — |
| Yezan Munther HaddadinDirector | $39K | — | Jun 3, 2026 | 36 |
| Randy H ThurmanDirector | $2K | — | May 27, 2026 | — |
| Lawrence A KenyonCFO | — | — | Aug 14, 2026 | — |
| Robert Charles JahrCEO | — | — | Aug 14, 2026 | — |
OTLK stock: common questions
Are Outlook Therapeutics, Inc. insiders buying OTLK stock?
In the past 12 months, 5 insiders reported open-market purchases of OTLK worth $7.9M. The latest was Director Ghiath M. Sukhtian bought $2.5M of OTLK at $0.99 — first open-market purchase in our records.
Are Outlook Therapeutics, Inc. insiders selling OTLK stock?
0 insiders reported sales worth $0 over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is OTLK's 52-week range?
Over the past year OTLK has traded between $0.20 and $2.47. It last closed at $0.60 on Oct 9, 2026.